Terug
21
38
48
35
35
Dagbereik
€ 41,39
€ 42,19
52-Weeksbereik
€ 32,38
€ 49,62
Volume
2.614.112
50D / 200D Gem.
€ 43,04
/
€ 41,57
Vorige Slotkoers
€ 41,27
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 14,2 | 0,4 |
| P/B | 5,1 | 2,9 |
| ROE % | 35,5 | 3,8 |
| Net Margin % | 33,7 | 3,9 |
| Rev Growth 5Y % | 12,8 | 10,0 |
| D/E | 0,1 | 0,2 |
Koersdoel Analisten
Hold
€ 44,11
+6.5%
Low: € 30,00
High: € 54,00
Forward K/W
14,1
Forward WPA
€ 2,95
WPA Groei (sch.)
+0,0%
Omzet Sch.
2,3 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2031 |
€ 5,48
€ 4,92 – € 5,98
|
3,2 B | 6 |
| FY2030 |
€ 5,57
€ 5,01 – € 6,09
|
3,4 B | 5 |
| FY2029 |
€ 4,77
€ 2,26 – € 7,45
|
3,3 B | 12 |
Belangrijkste Punten
Revenue grew 12,76% annually over 5 years — strong growth
Earnings grew 50,13% over the past year
ROE of 35,53% indicates high profitability
Net margin of 33,73% shows strong profitability
Debt/Equity of 0,08 — conservative balance sheet
Generating 844,34M in free cash flow
Groei
Revenue Growth (5Y)
12,76%
Revenue (1Y)6,98%
Earnings (1Y)50,13%
FCF Growth (3Y)122,63%
Kwaliteit
Return on Equity
35,53%
ROIC28,02%
Net Margin33,73%
Op. Margin37,59%
Veiligheid
Debt / Equity
0,08
Current Ratio3,56
Interest Coverage0,00
Waardering
P/E Ratio
14,19
P/B Ratio5,14
EV/EBITDA12,37
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 6,98% | Revenue Growth (3Y) | 12,59% |
| Earnings Growth (1Y) | 50,13% | Earnings Growth (3Y) | 94,08% |
| Revenue Growth (5Y) | 12,76% | Earnings Growth (5Y) | 35,66% |
| Profitability | |||
| Revenue (TTM) | 2,32B | Net Income (TTM) | 782,57M |
| ROE | 35,53% | ROA | 27,51% |
| Gross Margin | 96,39% | Operating Margin | 37,59% |
| Net Margin | 33,73% | Free Cash Flow (TTM) | 844,34M |
| ROIC | 28,02% | FCF Growth (3Y) | 122,63% |
| Safety | |||
| Debt / Equity | 0,08 | Current Ratio | 3,56 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 14,19 | P/B Ratio | 5,14 |
| P/S Ratio | 4,79 | PEG Ratio | 0,25 |
| EV/EBITDA | 12,37 | Dividend Yield | 0,00% |
| Market Cap | 11,10B | Enterprise Value | 10,79B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2,32B | 2,17B | 1,83B | 1,61B | 1,43B |
| Net Income | 782,57M | 521,27M | 207,77M | 182,28M | 231,06M |
| EPS (Diluted) | 2,78 | 1,76 | 0,65 | 0,56 | 0,72 |
| Gross Profit | 2,24B | 2,09B | 1,76B | 1,55B | 1,38B |
| Operating Income | 872,19M | 604,62M | 170,89M | 201,48M | 286,67M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2,84B | 2,95B | 2,94B | 3,07B | 2,62B |
| Total Liabilities | 683,10M | 703,49M | 678,45M | 583,06M | 405,62M |
| Shareholders' Equity | 2,16B | 2,24B | 2,26B | 2,49B | 2,21B |
| Total Debt | 173,04M | 190,82M | 189,94M | 190,17M | 51,27M |
| Cash & Equivalents | 482,49M | 217,37M | 262,99M | 501,20M | 647,17M |
| Current Assets | 1,44B | 1,47B | 1,32B | 1,62B | 1,83B |
| Current Liabilities | 405,64M | 403,77M | 394,28M | 324,36M | 337,59M |
Strategiescores
This stock passed the criteria for 5 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#938 of 1024
Custom
Capital Light Compounder
#124 of 213
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#185 of 326
Custom
Balanced Risk
#118 of 148
Custom
Lower Risk
#112 of 136
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Capital Light Compounder
Mar 24, 2026
Ingestapt
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Ingestapt
Balanced Risk
Mar 24, 2026
Ingestapt
Lower Risk
Mar 24, 2026